spacer
home > ebr > summer 2017 > upcycling genomics
PUBLICATIONS
European Biopharmaceutical Review

Upcycling Genomics

Gene therapies have taken centre stage in the medical field and interest is growing rapidly. For the first time, people can hope for a true cure of heritable disabilities by accessing a patientís genome, as opposed to being treated only symptomatically, and any acquired pathologies with genetic elements are part of this development. HIV, for example, Ďhidesí in blood cells by integrating into the hostís genome, making it nearly impossible to remove from the system without genetic means. Asthma, arthritis, hypertension and many forms of cancers are in part caused by environmental factors that throw our genetic or epi-genetic makeup out of whack.

Of course, the application of genetic tools to patients is a controversial issue, and the backlash of early trials gone wrong in the 1990s severely dampened the whole, a setback that would be felt for over 10 years in the research community. With the number of clinical studies slumping and little growth for a decade, the concurrent rise of improved gene tools, paired with a much deeper understanding of the mechanisms underlying gene delivery, prepared a veritable rebirth of this field.

Following the rise of CRISPR/Cas9 technologies, the number of therapeutic strategies has become as plentiful as the range of human afflictions. This new shift towards gene therapy brings a measurable need for the optimisation of gene delivery strategies to enable practitioners to better transport their candidate constructs in a more targeted therapeutic context. While systemic applications favour the development of adeno-associated virus vector systems, highly efficient lentiviral vectors stand out as the system of choice for ex vivo therapies of hematopoietic cells (HCs) and hematopoietic stem cells (HSCs).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Franziska C Ruf is Senior Key Accounts Manager at SIRION Biotech with strong experience in molecular and cellular biology and her immunologic and hematopoietic background. Franziska worked as Project Coordinator and a Post-Doctoral Researcher in the Department of Hematology and Oncology at Klinikum rechts der Isar, Technical University Munich, Germany, where she also received her PhD in the Laboratory of Stem Cell Physiology.
spacer
Dr Franziska C Ruf
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

White Papers

Pharmaceuticals and Healthcare Products

Turkish Cargo

Pharmaceuticals are requiring safe and reliable transportation for being highly temperature sensitive products. Thosepharmaceuticals are; diagnostics, vaccines drugs, sera, plasma, protein clinical trials, biotechnological material, pills and all kind of medicines. Turkish Cargo transports all kind of pharmaceuticals, and has been carrying out its operations of transporting and storing drugs and temperature-sensitive medical supplies successfully and with the experience of 80 years; since 1936.
More info >>

 
Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement